Lymphoma & Plasma Cell Disorders

MD IQ

Conference Coverage

R2-CHOP doesn’t improve survival in DLBCL

LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...

Pages